All videointerviews from ASCO/EHA/ICML 2021

Alvaro Alencar discusses which first-line treatment options might soon be established for newly diagnosed patients with mantle cell lymphoma who are not eligible for intensive therapy, what can be expected in terms of innovative approaches in the setting of R/R mantle cell lymphoma or marginal zone lymphoma and highlights the need for robust prognostic tools allowing stratification of treatment modalities.

Matthew Davids depicts the most interesting trial results in the field of CLL treatment at the EHA 2021 congress, gives an outlook on the most promising agents currently tested for use not only in elderly but also in young, fit CLL patients and talks about combinations that might be implemented as pillars of CLL treatment based on current trials.

Wojciech Jurczak gives an overview of the advantages of new BTK inhibitors, the results of the ALPINE trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory CLL/SLL and talks about which new developments can be expected in the field of innovative BTK inhibitors in the treatment of CLL and other indications.

Carol Moreno highlights the CLL study results from EHA and ICML, enlarges on fixed-duration regimens in CLL treatment, the importance of long-term follow-up findings obtained in important trials such as CLL14 and ELEVATE-TN as well as data from the ALPINE and ELEVATE-RR studies and shares her thoughts on the role of new agents such as zanubrutinib in the overall treatment landscape.

Anthony Mato talks about the study highlights presented at EHA and ICML, innovative treatment approaches currently tested for use in CLL that appear most promising and explains how the prognosis of CLL patients might change due to new therapies in the years to come and summarizes potential strategies to prevent and overcome resistance to targeted therapies.

Christian Buske relates to recent developments with respect to the role of BTK inhibitors and their potential future combination partners in the treatment of patients with Waldenström’s macroglobulinemia, the results of the iNNOVATE study and personalized treatment according to genotypes.
Roger Owen summarizes the status of emerging therapeutic agents for the treatment of patients with Waldenström’s macroglobulinemia, highlights those that appear most promising, even after failing BTK inhibitors, talks about how to guide treatment decisions, the influence of the mutation profile and expectations of BTK inhibitors in patients with relapsed and refractory marginal zone lymphoma.


All videointerviews from ASCO Lung Cancer 2021

Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.

David T. Cooke talks about health equity and health disparities relating to lung cancer management in the western world. He explains which factors based on ethnicity are likely to affect outcomes of lung cancer patients and how health disparities might be tackled in the long run at the public health level.

Donald R. Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.

Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.

Luis G. Paz-Ares explains which notable developments are taking place in the field of small-cell lung cancer with respect to new targets and targeted agents, how chemotherapeutic standards will change in the management of patients with small-cell lung cancer and highlights the most relevant findings presented at ASCO 2021 in terms of targeted therapies.


All videointerviews from WCLC 2020

Alex Spira highlights the advantages, shortcomings and the future potential of antibody-drug conjugates, the balance between pro- and anti-inflammatory cytokines within the tumor microenvironment, and the preclinical evidence for targeting inflammatory cytokines in advanced or metastatic non-small cell lung cancer.

Luis M. Montuenga talks about factors that are impeding the implementation of low-dose computed tomography lung cancer screening at the global level and describes biomarkers/molecular technologies that are promising with respect to early detection of lung cancer. Moreover, he summarizes advantages and drawbacks of pan-cancer ctDNA analysis in liquid biopsy.

Ming Tsao relates to the innovations of the 5th edition of the WHO classification of lung tumors in terms of additional chapters, new tumor types and grading systems. Additionally, he discusses the use of organoids as potential platforms for drug testing and biomarker validation, as well as miRNAs for early lung cancer detection.

Sandip Patel discusses immunotherapy regimens for the treatment of patients with extended-stage SCLC, immune-related adverse events and how to identify, predict and prevent checkpoint-inhibitor induced pneumonitis. Additionally, he talks about post-pandemic cancer care delivery and what oncologists should keep in mind when using anti-PD-1 therapy.


All videointerviews from ASH 2020

Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.

Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.


All videointerviews from ESMO Solid Tumors 2020

Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.

Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.


All videointerviews from ESMO Lung Cancer 2020

Tony Mok summarizes insights into the immunotherapeutic management of patients with advanced lung cancer who receive PD-1 inhibitors and relates to aspects of biomarker-based treatment selection, patient prognosis, and new agents that might change the treatment landscape.

Byoung Chul Cho explains about the rationale and outcomes for combined targeted treatment of lung cancer patients with an emphasis on EGFR-mutant disease and describes findings obtained for a first-in-class agent targeting the KRASG212C mutation.

Maarten Lambrecht highlights aspects of radiobiology regarding interactions between radiotherapy and the immune system, non-invasive imaging biomarkers and trial results presented at ESMO 2020 that bear importance from a radiation oncologist’s point of view.

Paul Baas discusses the prognosis and treatment of patients with malignant mesothelioma, relating to combined modality treatment with immune checkpoint inhibitors plus chemotherapy and talks about other immunotherapeutic approaches beyond checkpoint inhibition.


All videointerviews from EHA 2020

Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety, next-generation BTK inhibitors and recent developments in the management of cold agglutinin disease.

Constantine Tam depicts the most interesting trial results in the field of CLL treatment at the EHA congress and gives an outlook on future treatment options for CLL and mantle cell lymphoma.

Veronique Leblond highlights relevant factors for the selection of treatment in newly diagnosed and relapsed Waldenström’s macroglobulinemia, the connection of BTK inhibitors and MYD88 or CXCR4 mutations and discusses the risk-benefit profile of these drugs.

Peter Hillmen gives an overview of the most relevant treatment strategies in ­patients with paroxysmal nocturnal hemoglobinuria and further explains the advantages of proximal over terminal complement inhibition.


All videointerviews from ASCO 2019

Martin Reck gives an overview on where we are today regarding immunotherapies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.

Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.

Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.

Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.


All videointerviews from ELCC 2019

Pilar Garrido gives an overview of the management of patients with stage III NSCLC, novel treatments in stage III disease and recent insights concerning immune modulatory vaccination in patients with NSCLC.

Thomas Newsom-Davis on the treatment algorithm for ALK-positive NSCLC and future developments for patients with ALK/ROS1-positive tumors.

Nir Peled talks about the importance of early detection of lung cancer – especially in poorer countries –, promising biomarkers for the early detection and new insights into the interactions between lung cancer cells and the tumor microenvironment.

Anne-Marie Dingemans explains the importance of chemotherapy in the current management of NSCLC and promising new combinations of chemotherapeutic agents with other drug classes.


All videointerviews from ESMO 2019

Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.

Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.

Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.

Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.


All videointerviews from ESMO 2018

Sanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.

Luis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.


All videointerviews from WCLC 2018

Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Vera Hirsh discusses the latest clinical achievements using <em>EGFR</em>-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.


All videointerviews from ASCO 2018

Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.


All videointerviews from ASCO 2017

Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.

Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.

Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo – inOncology, and the approval of afatinib for EGFR+ NSCLC in China.

Maya Gottfried on NSCLC screening and treatment options.


All videointerviews from CSCO 2017

Caicun Zhou discusses NSCLC care in China, and the use of molecular targeted agents

Shun Lu discusses the recent clinical trial data for EGFR targeted agents and how this will shape clinical practice, as well as the need for solid clinical trial data revealing how the sequencing of EGFR directed agents affects survival


All videointerviews from ESMO 2017

Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.

Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.

Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.

Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.


All videointerviews from WCLC 2017

David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

Paul A. Bunn discusses current and future treatment options in lung cancer.


All videointerviews from ESMO 2016

Enriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.

Martin Reck discusses the management of immunotherapy related adverse events.

Pasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.

Anders Mellemgaard on anti-angiogenesis treatments


All videointerviews from WCLC 2016

Martin Schuler on the current state-of-play for EGFR diagnostic technologies

Johan Vansteenkiste discusses the practical considerations for immunotherapy

Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress

Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer

James Chih-Hsin Yang talks TKIs


Impressions from participants – Preceptorship 2016 Vienna

Participants of the inaugural Springer International Lung Cancer Preceptorship 2016 give their impressions of the meeting.